LUPIN News Today

Lupin Ltd Share Price

LUPIN

CMP as on 16-Apr-24 3:59
₹ 1,611

icon 2.35 | 0.15%

Open
₹ 1,606
Turnover(lac)
₹ 12,291
Prev. Close
₹ 1,609.10
Day's Vol (shares)
₹ 762,738
Day's Vol (shares)
₹ 1,600.10         ₹ 1,636.95

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Lupin launches generic version of doxycycline capsules in the US

The business got Form 483 from the USFDA in March, with one observation for its Aurangabad plant, following an inspection from March 6 to March 15.

  • 10 Apr, 2024 |
  • 2:28 PM
Image not found

Lupin names Christoph Funke as new Chief Technical Officer

He will be located in Mumbai and would be in charge of Lupin's technical operations.

  • 19 Mar, 2024 |
  • 11:06 AM
Image not found

Lupin launches generic fertility drug Ganirelix Acetate in the US

It is the generic equivalent of Organon USA LLC's Ganirelix Acetate Injection, 250 mcg/0.5 mL, which is reference listed (RLD).

  • 16 Feb, 2024 |
  • 9:26 AM
Image not found

Q3FY24 Review: Lupin: Aspiring for further margin expansion

Recommendation: Add; Target price: ₹1590

  • 09 Feb, 2024 |
  • 1:34 PM
Image not found

Lupin Soars: Q3 Revenue Up 20%, Net Profit Quadruples to ₹613 Crore

Revenue increased to ₹5,197.4 Crore from ₹4,322.2 Crore in the same quarter last year.

  • 08 Feb, 2024 |
  • 11:47 AM
Image not found

USFDA Nod for Stroke Drug Lifts Lupin Shares: Indian Pharma Giant Celebrates

Lupin was trading at Rs 1,455.55 on the BSE at 11:13 a.m., up Rs 16.25, or 1.15% .

  • 24 Jan, 2024 |
  • 11:11 AM
Image not found

Lupin Hits 52-Week High as FDA Greenlights Febuxostat Tablets for Gout Treatment in the U.S.

Febuxostat Tablets, with indications for managing hyperuricemia in adult gout patients, will be manufactured at Lupin's Pithampur facility in India

  • 19 Jan, 2024 |
  • 10:53 AM
Image not found

Lupin zooms ~2% on gaining USFDA approval for hypertension drug

Lupin has obtained approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)

  • 15 Jan, 2024 |
  • 2:29 PM
Image not found

Lupin Launches Bromfenac Ophthalmic Solution in the US, Securing 180-Day Exclusivity

The company holds exclusive first-to-file status, granting a 180-day exclusivity period for the newly-introduced product

  • 10 Jan, 2024 |
  • 1:55 PM
Image not found

Lupin hits 52-week high on tentative USFDA approval for dapagliflozin and saxagliptin tablets

Lupin plans to manufacture the drug at its Pithampur Facility in Madhya Pradesh.

  • 05 Jan, 2024 |
  • 11:32 AM